Actinogen cancels 2.8m shares under employee scheme buy-back

Actinogen Medical ( (AU:ACW) ) has issued an announcement.

Actinogen Medical has notified the market of the cessation of 2,833,335 ordinary fully paid shares, following their cancellation under an employee share scheme buy-back. The adjustment to issued capital reflects ongoing management of its employee incentive arrangements and may have a modest effect on the company’s capital structure and existing shareholders’ relative stakes.

The buy-back-related cancellation, effective 4 May 2026, removes these securities from quotation under the ACW code on the ASX. This type of transaction is a routine governance measure for listed companies and signals Actinogen Medical’s active oversight of its equity-based remuneration programs.

The most recent analyst rating on (AU:ACW) stock is a Buy with a A$0.08 price target. To see the full list of analyst forecasts on Actinogen Medical stock, see the AU:ACW Stock Forecast page.

More about Actinogen Medical

Actinogen Medical Limited is an ASX-listed biotechnology company focused on medical therapies, with its ordinary fully paid shares trading under the ticker ACW. The company operates within the life sciences sector and manages its capital structure in part through employee share schemes and associated buy-backs.

YTD Price Performance: -24.59%

Average Trading Volume: 3,231,187

Technical Sentiment Signal: Buy

Current Market Cap: A$165.2M

Learn more about ACW stock on TipRanks’ Stock Analysis page.